Investment Thesis
Kestra Medical is a pre-profitable medical device company with exceptional revenue growth (115% YoY) and a fortress balance sheet ($291M cash, 7.32x current ratio), but faces severe operational challenges with -$88.2M negative free cash flow and an operating margin of -143.5%, indicating unsustainable unit economics without significant operational leverage improvements.
Strengths
- Exceptional top-line growth of 115% YoY demonstrating strong market demand
- Fortress balance sheet with $291.3M in cash and minimal debt (0.15x D/E ratio) providing 3+ years of runway
- Healthy gross margin of 49.9% indicating viable core product economics
- Net losses improving 9.8% YoY suggesting operational trajectory toward profitability
- Excellent liquidity with 7.32x current ratio providing financial flexibility
Risks
- Severe unprofitability with -$139.5% net margin and -$143.5% operating margin indicating massive SG&A/R&D spend relative to revenue
- Negative operating cash flow of -$63.0M and negative free cash flow of -$88.2M showing company burns $1.33 for every $1.00 in revenue
- No visible path to profitability in current trajectory requiring dramatic margin expansion or revenue acceleration to achieve breakeven
- Medical device sector execution risk with long development and commercialization cycles vulnerable to regulatory, clinical, or market adoption delays
- Cash burn rate of $88.2M annually will require either additional capital raises or rapid profitability improvements within 3+ years
Key Metrics to Watch
- Operating cash flow trajectory and path to positive OCF relative to revenue growth
- Gross margin sustainability and expansion potential as manufacturing scales
- Operating expense ratio relative to revenue - need to see SG&A and R&D leverage
- Quarterly revenue growth sustainability - whether 115% growth rate can be maintained
- Free cash flow breakeven timeline and cash runway depletion estimates
Financial Metrics
Revenue
66.5M
Net Income
-92.8M
EPS (Diluted)
$-1.76
Free Cash Flow
-88.2M
Total Assets
379.3M
Cash
291.3M
Profitability Ratios
Gross Margin
49.9%
Operating Margin
-143.5%
Net Margin
-139.5%
ROE
-32.2%
ROA
-24.5%
FCF Margin
-132.7%
Balance Sheet & Liquidity
Current Ratio
7.32x
Quick Ratio
7.32x
Debt/Equity
0.15x
Debt/Assets
24.1%
Interest Coverage
N/A
Long-term Debt
42.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-12T03:51:27.072125 |
Data as of: 2026-01-31 |
Powered by Claude AI